Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 16/20 | 0.65 |
| ▸ | NPY1R | P25929 | 10/20 | 0.65 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.65 |
| ▸ | NPY2R | P49146 | 6/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649727 | 1.00 | NPY4R (0.65) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30331385 | 0.95 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL31345750 | 0.93 | NPY4R (0.64) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL4449035 | 0.93 | NPY4R (0.74) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29559026 | 0.92 | NPY4R (0.60) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL31412176 | 0.92 | NPY4R (0.54) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3303678 | 0.92 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL3993177 | 0.92 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30392718 | 0.92 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL7248017 | 0.92 | NPY4R (0.68) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | claimed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | claimed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | HAIKOU QIAOSHUI UNITED TECHNOLOGY CO. LTD. (CN) | 2026-03-12 | — | — | US | disclosed |
| CN-118987163-A | Use of sardine peptide-containing composition for improving atopic dermatitis symptoms | 海口桥水联合科技有限责任公司 | 2024-11-22 | — | — | CN | disclosed |
| WO-2024235082-A1 | USE OF SARDINE PEPTIDE COMPOSITION IN DRUG FOR TREATING ALLERGIC RHINITIS | 海口桥水联合科技有限责任公司 | 2024-11-21 | — | — | WO | disclosed |
| EP-4337675-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Universidad De Chile (CL) | 2024-03-20 | — | — | EP | disclosed |
| EP-4284779-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022238734-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022165189-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11331368-B2 | Angiotensin receptor agonists and uses thereof | MONASH UNIVERSITY (AU) | 2022-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069651-A1 | Application of Sardine Peptide Composition in Drug for Treating Allergic Rhinitis | VIP, ANPEP, RNPEP | NPY4R 708/4885NPY1R 438/4885NPY5R 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.